Allosteric rescuing of loss-of-function FFAR2 mutations

FEBS Letters

Volumn 584, Issue 19, 2010, Pages 4208-4214

  Swaminath, Gayathri ^a   Jaeckel, Peter ^b   Guo, Qi ^a   Cardozo, Mario ^a   Weiszmann, Jennifer ^a   Lindberg, Richard ^a   Wang, Yingcai ^a   Schwandner, Ralf ^b   Li, Yang ^a  

^a AMGEN INC   (United States)

^b Amgen Research GmbH   (Germany)

Author keywords

Allosteric agonist; AMG7703; FFA2; Free fatty acid receptor 2; GPR43; Short chain fatty acids

Indexed keywords

ACETANILIDE; ACETIC ACID; BETA 2 ADRENERGIC RECEPTOR; FREE FATTY ACID RECEPTOR 2; PROPIONIC ACID; PROTEIN GPR43; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIGAND BINDING; LOSS OF FUNCTION MUTATION; MUTAGENESIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ACETAMIDES; ACETIC ACID; ALLOSTERIC REGULATION; ALLOSTERIC SITE; AMINO ACID MOTIFS; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS;

EID: 77957114912     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.09.007     Document Type: Article

References (28)

1. Sawzdargo M., George S.R., Nguyen T., Xu S., Kolakowski L.F., O'Dowd B.F. A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem. Biophys. Res. Commun. 1997, 239:543-547.
2. Rayasam G.V., Tulasi V.K., Davis J.A., Bansal V.S. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin. Ther. Targets 2007, 11:661-671.
3. Brown A.J., et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278:11312-11319.
4. Nilsson N.E., Kotarsky K., Owman C., Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem. Biophys. Res. Commun. 2003, 303:1047-1052.
5. Le Poul E., et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 2003, 278:25481-25489.
6. Stoddart L.A., Smith N.J., Milligan G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol. Rev. 2008, 60:405-417.
7. Ge H., Li X., Weiszmann J., Wang P., Baribault H., Chen J.-L., Tian H., Li Y. Activation of GPR43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008, 149:4519.
8. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 2005, 258:94-114.
9. Swaminath G. Fatty acid binding receptors and their physiological role in type 2 diabetes. Arch. Pharm. (Weinheim) 2008, 341:753-761.
10. Nagasumi K., et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009, 58:1067-1076.
11. Tikhonova I.G., Sum C.S., Neumann S., Thomas C.J., Raaka B.M., Costanzi S., Gershengorn M.C. Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. J. Med. Chem. 2007, 50:2981-2989.
12. Sum C.S., Tikhonova I.G., Neumann S., Engel S., Raaka B.M., Costanzi S., Gershengorn M.C. Identification of residues important for agonist recognition and activation in GPR40. J. Biol. Chem. 2007, 282:29248-29255.
13. Stoddart L.A., Smith N.J., Jenkins L., Brown A.J., Milligan G. Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J. Biol. Chem. 2008, 283:32913-32924.
14. Lee T., et al. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol. Pharmacol. 2008, 74:1599-1609.
15. Wang Y., et al. The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. Bioorg. Med. Chem. Lett. 2010, 20:493-498.
16. Jacobson M.P., Pincus D.L., Rapp C.S., Day T.J., Honig B., Shaw D.E., Friesner R.A. A hierarchical approach to all-atom protein loop prediction. Proteins 2004, 55:351-367.
17. Maestro. Maestro 8.5.110. Schrodinger, LLC. New York NY, 2008.
18. Cherezov V., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
19. Palczewski K., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289:739-745.
20. Teller D.C., Okada T., Behnke C.A., Palczewski K., Stenkamp R.E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001, 40:7761-7772.
21. Scheer A., Fanelli F., Costa T., De Benedetti P.G., Cotecchia S. Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. Embo. J. 1996, 15:3566-3578.
22. Greasley P.J., Fanelli F., Rossier O., Abuin L., Cotecchia S. Mutagenesis and modelling of the alpha(1b)-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation. Mol. Pharmacol. 2002, 61:1025-1032.
23. Rovati G.E., Capra V., Neubig R.R. The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol. Pharmacol. 2007, 71:959-964.
24. Langmead C.J., Christopoulos A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol. Sci. 2006, 27:475-481.
25. May L.T., Leach K., Sexton P.M., Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2007, 47:1-51.
26. Lazareno S., Dolezal V., Popham A., Birdsall N.J. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 2004, 65:257-266.
27. Shirey J.K., et al. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat. Chem. Biol. 2008, 4:42-50.
28. Nawaratne V., Leach K., Felder C.C., Sexton P.M., Christopoulos A. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J. Biol. Chem. 2010, 285:19012-19021.